PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12
PerkinElmer Inc. has entered into a global licensing agreement with the University of Copenhagen in Copenhagen, Denmark, to develop assay kits for the biochemical marker ADAM12. ADAM12 has broad potential in maternal health screening as a marker for fetal chromosomal abnormalities as well as for intrauterine growth retardation (IUGR) and pre-eclampsia, both of which can result in, maternal, fetal and long-term complications if left undiagnosed.
The license agreement covers exclusivity in North America and co-exclusivity in Europe, Central and South America. Kits will be developed for the complete portfolio of PerkinElmer platforms, including AutoDELFIA, DELFIA Xpress and manual DELFIA platforms.
A team consisting of Dr. Ulla Wewer at the University of Copenhagen, Dr. Michael Christiansen from Statens Serum Institut (SSI) and Dr. Kevin Spencer at the Harold Wood Hospital in England have done all of the groundwork and tested ADAM12 in several thousand samples from pregnant women to investigate its importance for prediction of chromosomal disorders.
ADAM12 also shows potential to provide an early indicator of IUGR and pre-eclampsia, for which there are no current screening mechanisms. Early studies at the University of Copenhagen, SSI and Harold Wood have shown that ADAM12 levels were reduced at 10-14 weeks in pregnancies that developed pre-eclampsia and were greatly reduced in those exhibiting both pre-eclampsia and low birth weight.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
How can we fight blood cancer more effectively? - Several hundred different treatment combinations to be tested simultaneously outside the body
LGC announces plans to expand forensic services with new facilities to be created in Runcorn, Cheshire
Synthetic Production of Potential Pharmaceuticals Dramatically Simplified by Scripps Research Team - Findings Could Expand Interest in Natural Products by Making Production More Cost-Effective
Light-induced shape shifting of MXenes - Femtosecond light creates switchable nano-waves in MXenes and moves the materials’ atoms at a record-breaking speed
Brooks Instrument Joins Major Biotechnology Consortium Focused on Regenerative Drug Manufacturing - Brooks Instrument will contribute insights and precision fluid control technology to the Advanced Regenerative Manufacturing Institute’s BioFabUSA program
Promising discovery for a non-invasive early detection of Alzheimer's disease
Innovations through hair-thin optical fibres - Study shows what miniaturised optical filters make possible
Wave of the future - Terahertz chips a new way of seeing through matter
Using PETRA III to watch the disabling of a penicillin killer - Scientists observe in detail the binding and formation of covalent bonds of an inhibitor to a bacterial enzyme that disables common antibiotics
Eurofins acquires LGC Forensics
How pathogenic bacteria prepare a sticky adhesion protein
